Genetic Testing Of Patients With Gastrointestinal Cancer Prior To Starting Chemotherapy Proved Feasible, Showed Signal For A Reduced Risk Of Serious Side Effects, Study Indicates

MedPage Today (8/11, Bassett) reports, “Genetic testing of” patients with “gastrointestinal cancer...prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects.” Investigators found that “compared with patients who received standard dose chemotherapy, those who had a tailored dose of chemotherapy based on rapid genetic testing for variants in DPYD and UGT1A1 had more treatment modifications...as well as numerically fewer severe treatment-related adverse events...and treatment discontinuations.” The findings were published in JCO Precision Oncology.